| Filed On | Filing |
|---|---|
| 28 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of August 28, 2026, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agree... |
| 23 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +5 more
Certificate of Merger, including certificate of incorporation of the Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 15, 2026 (the Meeting), two proposals were voted upon by the Company’s stockholders. The proposals are described in detail in the Company’s definitiv... |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 |
| 13 Apr 2026 |
8-K: Termination of a Material Definitive Agreement; Creation of a Direct Financial Obligation
On April 13, 2026, Boundless Bio, Inc. (the "Company") entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the "Lease Termination Agreement") with ARE-10933 North Torrey Pines, LLC ("Landlord"), pursua... |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 23, 2025 (the Meeting), two proposals were voted upon by the Company’s stockholders. The proposals are described in detail in the Company’s definitiv... |
| 23 May 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Other Events
On May 23, 2025, Boundless Bio, Inc. (the Company), in connection with the portfolio prioritization described below, announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 |
| 01 Apr 2025 |
8-K: Entry into a Material Definitive Agreement
On April 1, 2025, Boundless Bio, Inc. (the Company) entered into an Open Market Sale AgreementSM (the Sales Agreement) with Jefferies LLC (the Agent), under which the Company may, from time to time, sell shares of the Company’s common st... |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition
BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 |
| 12 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 |
| 15 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 14, 2024, Boundless Bio, Inc. (the “Company”) announced that Jami Rubin, the Company’s Chief Financial Officer and Treasurer, stepped down from her role with the Company. Ms. Rubin’s employment with the Company terminated effe... |
| 20 Aug 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective August 19, 2024, the compensation committee of the board of directors of Boundless Bio, Inc. (the “Company”) approved an option repricing (the “Repricing”) of the outstanding stock options held by certain employees, including o... |
| 12 Aug 2024 |
8-K: Results of Operations and Financial Condition
BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 |
| 13 May 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications |
| 02 Apr 2024 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
The address of the registered office of Boundless Bio, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporation, as t... |
Loading...